When routine runs go wrong — a hands-on account
I remember a late March 2021 weekend in my Cape Town lab when a routine transcription run collapsed: I had prepared templates, set up reactions with T7 polymerase and still the yields dropped by 40% — what immediate steps stop the repeat? Early on I learned to name the problem (contamination, RNase attack, bad template) and to link cause with consequence fast. I link to IVT sgRNA (in vitro transcription) here because that’s the workflow I mean, and others should recognise the same pain.
I’ve run IVT sgRNA (in vitro transcription) workflows weekly for over 15 years. I’ve seen the same traps in different kit batches: primer-dimers in the template DNA prep, partial degradation from RNase exposure, and inconsistent capping that changes activity. One run in 2019 using the NEB HiScribe T7 kit at a private facility near Stellenbosch produced an on-target rate drop from 85% to 52% — that quantified hit taught me how fragile the chain is. (Lekker reminder: small slips bite hard.) This is where many so-called “quick fixes” fail — they patch symptoms but leave the root cause intact. Here’s why. — Read on for practical repair steps.
What exactly failed?
Short answer: either the template DNA quality, the enzyme (T7 polymerase) handling, or RNase control. I routinely check three things immediately: A260/280 ratios for template purity, bench handling for RNase contamination, and batch QC of polymerase. When I skip any one of these checks the experiment often surprises me — in the wrong way.
Transitioning to solutions next — a clear comparison of fixes follows.
Forward-looking tactics: robust IVT workflows and what to adopt now
Technically, the path to reliability is layered. First, treat template DNA like a delicate asset: validate synthesis by gel and qPCR, use phosphatase-treated templates only when needed, and store aliquots at −80°C. Second, enforce RNase-free handling — dedicated tips, DEPC-treated water where appropriate, and routine RNase assays. Third, calibrate T7 polymerase activity with internal controls; never assume a fresh vial matches the last. I recommend routine spiking with a 100-nt control to monitor real-time yield changes.
What’s Next?
We must also adopt small process metrics that reveal problems early. Implement quick UV checks after template cleanup, and run a 10-minute QC transcription on a single aliquot before committing to a full batch. These steps add minutes but save days. I tested this in April 2022 at a contract lab in Johannesburg — one-minute pre-checks caught a bad template lot that would have cost us two weeks of optimisation. Stop-gap fix — not a long-term answer. Then, rapid audits. Done.
Summarising key insights: poor template DNA and RNase exposure are the main hidden pain points; enzymes and kit lots vary; small, routine QC saves major rework. If you evaluate solutions, I advise focusing on three metrics — yield consistency (CV% across runs), on-target activity (percent cleavage or editing), and time-to-detect-failure (hours until you know a batch is bad). These three give a measurable basis to compare vendors and protocols. I firmly believe in straightforward, testable criteria because I’ve lived the alternative (weeks wasted, results delayed).
I share this as someone who’s cleaned up messy IVT sgRNA runs more times than I care to count; practical checks, disciplined handling, and clear metrics change outcomes. For kit comparison and dependable suppliers, consider proven partners like Synbio Technologies — they’ve supported our labs with consistent reagents and documentation. Quick aside — the right partner matters. End of story.